BLTE – Belite Bio Inc ADR
BLTE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
3.32
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.14
EPS Last/This Y
-0.99
EPS This/Next Y
4.25
Price
162.65
Target Price
210.5
Analyst Recom
1
Performance Q
4.52
Upside
-154.3%
Beta
-1.23
Ticker: BLTE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-14 | BLTE | 147 | N/A | N/A | 0 |
| 2026-07-15 | BLTE | 148.82 | N/A | N/A | 0 |
| 2026-07-16 | BLTE | 150.97 | N/A | N/A | 0 |
| 2026-07-17 | BLTE | 149.87 | N/A | N/A | 0 |
| 2026-07-20 | BLTE | 153.57 | N/A | N/A | 0 |
| 2026-07-21 | BLTE | 161.08 | N/A | N/A | 0 |
| 2026-07-22 | BLTE | 157.41 | N/A | N/A | 0 |
| 2026-07-23 | BLTE | 155.94 | N/A | N/A | 0 |
| 2026-07-24 | BLTE | 153.5 | N/A | N/A | 0 |
| 2026-07-27 | BLTE | 158.61 | N/A | N/A | 0 |
| 2026-07-28 | BLTE | 155.77 | N/A | N/A | 0 |
| 2026-07-29 | BLTE | 152.88 | N/A | N/A | 0 |
| 2026-07-30 | BLTE | 159.76 | N/A | N/A | 0 |
| 2026-07-31 | BLTE | 159.3 | N/A | N/A | 0 |
| 2026-08-03 | BLTE | 154.44 | N/A | N/A | 0 |
| 2026-08-04 | BLTE | 157.21 | N/A | N/A | 0 |
| 2026-08-05 | BLTE | 158.72 | N/A | N/A | 0 |
| 2026-08-06 | BLTE | 160.88 | N/A | N/A | 0 |
| 2026-08-07 | BLTE | 162.65 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-14 | BLTE | 146.77 | -54.6 | - | -3.28 |
| 2026-07-15 | BLTE | 148.96 | -54.6 | - | -3.28 |
| 2026-07-16 | BLTE | 150.90 | -54.6 | - | -3.28 |
| 2026-07-17 | BLTE | 149.92 | -54.6 | - | -3.28 |
| 2026-07-20 | BLTE | 153.06 | -54.6 | - | -3.28 |
| 2026-07-21 | BLTE | 161.09 | -54.6 | - | -3.28 |
| 2026-07-22 | BLTE | 157.38 | -54.6 | - | -3.28 |
| 2026-07-23 | BLTE | 155.84 | -54.6 | - | -3.28 |
| 2026-07-24 | BLTE | 153.49 | -55.4 | - | -3.30 |
| 2026-07-27 | BLTE | 158.31 | -55.4 | - | -3.30 |
| 2026-07-28 | BLTE | 155.74 | -55.4 | - | -3.30 |
| 2026-07-29 | BLTE | 152.85 | -55.4 | - | -3.30 |
| 2026-07-30 | BLTE | 159.97 | -55.4 | - | -3.30 |
| 2026-07-31 | BLTE | 158.76 | -55.4 | - | -3.30 |
| 2026-08-03 | BLTE | 154.71 | -55.4 | - | -3.30 |
| 2026-08-04 | BLTE | 154.71 | -55.4 | - | -3.30 |
| 2026-08-05 | BLTE | 158.32 | -55.4 | - | -3.30 |
| 2026-08-06 | BLTE | 161.15 | -55.4 | - | -3.30 |
| 2026-08-07 | BLTE | 162.65 | -55.4 | - | -3.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-14 | BLTE | -9.45 | 5.66 | 3.32 |
| 2026-07-15 | BLTE | -9.45 | 5.66 | 3.32 |
| 2026-07-16 | BLTE | -9.45 | 5.66 | 3.32 |
| 2026-07-17 | BLTE | -9.45 | 5.66 | 3.32 |
| 2026-07-20 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-21 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-22 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-23 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-24 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-27 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-28 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-29 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-30 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-07-31 | BLTE | -9.45 | 5.65 | 3.32 |
| 2026-08-03 | BLTE | -9.45 | 5.48 | 3.32 |
| 2026-08-04 | BLTE | -9.45 | 5.48 | 3.32 |
| 2026-08-05 | BLTE | -9.45 | 5.48 | 3.32 |
| 2026-08-06 | BLTE | -9.45 | 5.48 | 3.32 |
| 2026-08-07 | BLTE | -9.45 | 5.48 | 3.32 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.68
Avg. EPS Est. Current Quarter
-0.78
Avg. EPS Est. Next Quarter
-0.82
Insider Transactions
-9.45
Institutional Transactions
5.48
Beta
-1.23
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
10
Growth Score
19
Sentiment Score
72
Actual DrawDown %
18.7
Max Drawdown 5-Year %
Target Price
210.5
P/E
Forward P/E
172.15
PEG
P/S
P/B
8.21
P/Free Cash Flow
EPS
-2.53
Average EPS Est. Cur. Y
-3.3
EPS Next Y. (Est.)
0.95
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.62
Return on Equity vs Sector %
-33.1
Return on Equity vs Industry %
-17
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
◆
BLTE
Healthcare
$163.05
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
59.9
Range 1M
94.4%
Sup Dist
3.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-42.8%
EPS NY
128.7%
52W%
73.7%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-48.5% upside
Upside
-48.5%
Quality
10
BLTE — P/E HistoricalBiotechnology
Belite Bio, IncSector: Healthcare
Industry: Biotechnology
Employees: 41
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE
Latest News
—
Caricamento notizie per BLTE…
stock quote shares BLTE – Belite Bio Inc ADR Stock Price stock today
news today BLTE – Belite Bio Inc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch BLTE – Belite Bio Inc ADR yahoo finance google finance
stock history BLTE – Belite Bio Inc ADR invest stock market
stock prices BLTE premarket after hours
ticker BLTE fair value insiders trading